#itacitinib

Itacitinib Prophylaxis Reduces the Incidence of CRS, ICANS in IEC Therapy | ASH Clinical News | American Society of Hematology

For patients undergoing CD19-directed #CARTcell therapy, #itacitinib prophylaxis effectively reduced the incidence and severity of #cytokine release syndrome (CRS), with just 17.4% of patients experiencing grade ≥2 CRS compared with 56.5% on placebo: ow.ly/9y5l50W4mYU
#HemeSky #MedSky